0001493152-24-047445.txt : 20241122 0001493152-24-047445.hdr.sgml : 20241122 20241122170015 ACCESSION NUMBER: 0001493152-24-047445 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20241122 DATE AS OF CHANGE: 20241122 EFFECTIVENESS DATE: 20241122 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Dare Bioscience, Inc. CENTRAL INDEX KEY: 0001401914 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 204139823 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-530296 FILM NUMBER: 241490724 BUSINESS ADDRESS: STREET 1: 3655 NOBEL DRIVE STREET 2: SUITE 260 CITY: SAN DIEGO STATE: CA ZIP: 92122 BUSINESS PHONE: 858-926-7655 MAIL ADDRESS: STREET 1: 3655 NOBEL DRIVE STREET 2: SUITE 260 CITY: SAN DIEGO STATE: CA ZIP: 92122 FORMER COMPANY: FORMER CONFORMED NAME: Cerulean Pharma Inc. DATE OF NAME CHANGE: 20090714 FORMER COMPANY: FORMER CONFORMED NAME: Tempo Pharmaceuticals Inc DATE OF NAME CHANGE: 20070604 D 1 primary_doc.xml X0708 D LIVE 0001401914 Dare Bioscience, Inc. 3655 NOBEL DRIVE SUITE 260 SAN DIEGO CA CALIFORNIA 92122 858-926-7655 DELAWARE None Cerulean Pharma Inc. Tempo Pharmaceuticals Inc Corporation true Sabrina Martucci Johnson 3655 Nobel Drive Suite 260 San Diego CA CALIFORNIA 92122 Executive Officer Director President and Chief Executive Officer MarDee Haring-Layton 3655 Nobel Drive Suite 260 San Diego CA CALIFORNIA 92122 Executive Officer Chief Accounting Officer William H. Rastetter 3655 Nobel Drive Suite 260 San Diego CA CALIFORNIA 92122 Director Jessica Grossman 3655 Nobel Drive Suite 260 San Diego CA CALIFORNIA 92122 Director Susan L. Kelley 3655 Nobel Drive Suite 260 San Diego CA CALIFORNIA 92122 Director Gregory W. Matz 3655 Nobel Drive Suite 260 San Diego CA CALIFORNIA 92122 Director Robin Steele 3655 Nobel Drive Suite 260 San Diego CA CALIFORNIA 92122 Director Biotechnology Decline to Disclose 06b false 2024-10-21 true true false 0 15000000 0 15000000 The issuer entered into an equity line arrangement under which, subject to the terms thereof, the investor committed to purchase up to $15.0 million of common stock. In exchange for such commitment, the issuer issued 137,614 shares to the investor. false 1 0 0 Please refer to the clarification of response contained in Item 13 for more information. 0 The issuer intends to use any proceeds for working capital and general corporate purposes. false Dare Bioscience, Inc. /s/ MarDee Haring-Layton MarDee Haring-Layton Chief Accounting Officer 2024-11-22